Exemplifying this is a study by Hu et al. in which they demonstrated that Bezafibrate, a pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist commonly used in diabetes management, enhances the efficacy of GSK126, a selective EZH2 inhibitor, in pancreatic cancer cells (Hu et al. 2021). The gene discussed is PPARA; the disease is familial pancreatic carcinoma.